Gilead price target raised to $100 from $95 at TD Cowen

TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a strong top and bottom beat which was driven by HIV liver disease and Trodelvy, but partially offset by misses with cell therapy and Veklury. FY25 product sales guidance bracketed consensus as the negative year-over-year impact due to Part D reform was well forecasted.